Sector News

Merck promotes 3 executives to lead human health business

February 20, 2022
Life sciences

Merck is looking for stability at the top of its human health business after turnover in the past year.

Frank Clyburn, who most recently served as president of the human health business, last month announced he would depart to take the CEO role at IFF, a New York-based maker of ingredients for food, fragrances and health products.

Clyburn hadn’t yet served a year in the position. He took over in March 2021 from Michael Nally, who himself left for a CEO job at another company.

The New Jersey-based drugmaker has been rebuilding its leadership team after the departure of long-time CEO Kenneth Frazier and research chief Roger Perlmutter in 2021. While the company is conducting an external search for its new Human Health International chief, its other choices show a willingness to promote from within.

Garay has been with the company since 2006 and previously led pharmaceutical global marketing, commercial analytics and digital marketing. Oosthuizen, who formerly helmed Merck’s business in Japan as well as oncology operations in the Asia Pacific and Latin America, has worked at the company since 2014 after a two-decade career at Eli Lilly.

Khanna, meanwhile, has been at Merck since 1988, working his way up from field sales to top roles in the oncology business. The three executives will assume their human health posts as of Feb. 28. They will sit on the executive team and report directly to CEO Robert Davis, Merck said.

By Kristin Jensen


comments closed

Related News

February 25, 2024

Pharma CFOs need R&D vigilance in tough economic times

Life sciences

As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.

February 25, 2024

Agilent CEO Mike McMullen to retire, succeeded by lab services head

Life sciences

McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.

February 25, 2024

AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn

Life sciences

AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.

How can we help you?

We're easy to reach